Spots Global Cancer Trial Database for A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Official Title: A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Study ID: NCT01469130
Conditions
Interventions
Study Description
Brief Summary: In this study, MEK162 will be administered to Japanese patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will investigate the safety and tolerability and determine the MTD of MEK162 in Japanese patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pfizer Investigative Site, Nagoya-city, Aichi, Japan
Pfizer Investigative Site, Yufu, Oita, Japan
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
